Analysts have clear opinions on CTLT.
There are 3 analysts on the Wall offering 12 month price targets for Catalent in the last 3 months. The average price target is $69.67 with a high forecast of $75.00 and a low forecast of $67.00. The average price target represents a 17.43% increase from the last price of $59.33.
Catalent, Inc. (CTLT) is followed by 3 analysts on the street.
Ricky Goldwasser from Morgan Stanley rates it a Buy with a target of $67.00.
Similarly, 8 days ago Evan Stover of Robert W. Baird Reiterated a Buy with a target of $67.00.
The consensus on the street is null.
What does Catalent, Inc.(CTLT) do ?
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
Catalent, Inc. (CTLT) Insider Trades
Multiple company employees have indulged in significant insider trading. Catalent, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
Pres, COO, Maselli Alessandro : S – Sale(-$386,512) of CTLT in the trading session of 2019-12-16.
SVP, CHRO Pravda Ricardo : S – Sale(-$137,718) of CTLT in the trading session of 2019-11-26.
Pres Softgel, Oral Tech Gennadios Aristippos : S – Sale+OE(-$2,378,203) of Catalent, Inc. in the trading session of 2019-11-25.
Looking for stocks just like CTLT?
Based on Wall Street analyst research, several stocks are similar to CTLT
– PFE [Info can be found here: https://www.nasdaq.com/market-activity/stocks/PFE ]
– MNKD [Info can be found here: https://www.nasdaq.com/market-activity/stocks/MNKD ]
– RHHBY [Info can be found here: https://www.nasdaq.com/market-activity/stocks/RHHBY ]